We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

32 hedge funds and large institutions have $25.9M invested in Xenon Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 31 → 32 (+1)

0.92% less ownership

Funds ownership: 51.79% → 50.87% (-0.92%)

6% less capital invested

Capital invested by funds: $27.5M → $25.9M (-$1.63M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
32
Holders Change
+1
Holders Change %
+3.23%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
6
Increased
8
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SSA
Schonfeld Strategic Advisors
New York
+$299K
2
Renaissance Technologies
Renaissance Technologies
New York
+$252K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$205K
4
KPF
K2 Principal Fund
Ontario, Canada
+$150K
5
DMK
David M. Knott
+$133K

Top Sellers

1
SFM
Sphera Funds Management
Israel
-$673K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$544K
3
Deutsche Bank
Deutsche Bank
Germany
-$274K
4
JGC
J. Goldman & Co
New York
-$214K
5
IPC
Invesco Private Capital
New York
-$92.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$10.1M – – –
Capital World Investors
2
Capital World Investors
California
$4.04M – – –
O
3
OrbiMed
New York
$1.79M – – –
SSA
4
Schonfeld Strategic Advisors
New York
$1.09M +$299K +110,000 +40%
DCM
5
DAFNA Capital Management
California
$1.07M – – –
TCM
6
Tekla Capital Management
Massachusetts
$989K – – –
IPC
7
Invesco Private Capital
New York
$968K -$92.2K -33,900 -9%
SM
8
Sabby Management
Florida
$931K +$59.3K +21,800 +7%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$876K – – –
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$704K -$544K -200,000 -45%
Renaissance Technologies
11
Renaissance Technologies
New York
$703K +$252K +92,600 +59%
KPF
12
K2 Principal Fund
Ontario, Canada
$620K +$150K +55,033 +33%
AG
13
Artal Group
Luxembourg
$424K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$330K +$205K +75,519 +183%
DMK
15
David M. Knott
$266K +$133K +49,000 +109%
State of New Jersey Common Pension Fund D
16
State of New Jersey Common Pension Fund D
New Jersey
$184K – – –
SC
17
Scotia Capital
Ontario, Canada
$178K +$23.2K +8,547 +16%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$155K – – –
DS
19
DRW Securities
Illinois
$85K +$81.6K +30,000 New
Stifel Financial
20
Stifel Financial
Missouri
$63K +$1.36K +500 +2%
NSEDCP
21
NJ State Employees Deferred Compensation Plan
New Jersey
$57K – – –
LWIC
22
Leith Wheeler Investment Counsel
British Columbia, Canada
$45K – – –
RC
23
RBF Capital
California
$43K +$41K +15,100 New
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$31K +$30.2K +11,120 New
Morgan Stanley
25
Morgan Stanley
New York
$30K +$28.1K +10,325 New
1
2

XENE Hedge Fund Activity: Q4 2017 in Review

32 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2017, worth a combined $25.9M — down 5.9% from $27.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 3 trimmed.

The largest buyer was Schonfeld Strategic Advisors, adding an estimated $299K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $673K sold.

  • 32 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2017, up from 31 in Q3 2017.
  • Funds reported $25.9M of Xenon Pharmaceuticals stock for Q4 2017, down 5.9% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q4 2017 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q4 2017 was Schonfeld Strategic Advisors, an estimated $299K added.
  • The largest Xenon Pharmaceuticals seller in Q4 2017 was Sphera Funds Management, an estimated $673K sold.

Based on aggregated 13F filings for Q4 2017.